- Home
- GLUE vs PSTL Comparison
GLUE vs PSTL Comparison
Compare GLUE & PSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLUE
- PSTL
- Stock Information
- Founded
- GLUE 2019
- PSTL 2018
- Country
- GLUE United States
- PSTL United States
- Employees
- GLUE N/A
- PSTL N/A
- Industry
- GLUE Biotechnology: Pharmaceutical Preparations
- PSTL Real Estate Investment Trusts
- Sector
- GLUE Health Care
- PSTL Real Estate
- Exchange
- GLUE Nasdaq
- PSTL Nasdaq
- Market Cap
- GLUE 351.2M
- PSTL 329.8M
- IPO Year
- GLUE 2021
- PSTL 2019
- Fundamental
- Price
- GLUE $4.80
- PSTL $15.84
- Analyst Decision
- GLUE Buy
- PSTL Strong Buy
- Analyst Count
- GLUE 2
- PSTL 1
- Target Price
- GLUE $13.50
- PSTL $17.75
- AVG Volume (30 Days)
- GLUE 369.2K
- PSTL 149.9K
- Earning Date
- GLUE 08-07-2025
- PSTL 08-04-2025
- Dividend Yield
- GLUE N/A
- PSTL 6.12%
- EPS Growth
- GLUE N/A
- PSTL 344.13
- EPS
- GLUE 0.29
- PSTL 0.39
- Revenue
- GLUE $177,986,000.00
- PSTL $86,535,000.00
- Revenue This Year
- GLUE $83.76
- PSTL $22.00
- Revenue Next Year
- GLUE N/A
- PSTL $9.76
- P/E Ratio
- GLUE $16.32
- PSTL $40.92
- Revenue Growth
- GLUE 2990.57
- PSTL 26.43
- 52 Week Low
- GLUE $3.50
- PSTL $12.26
- 52 Week High
- GLUE $12.40
- PSTL $15.84
- Technical
- Relative Strength Index (RSI)
- GLUE 51.69
- PSTL 70.89
- Support Level
- GLUE $4.54
- PSTL $15.31
- Resistance Level
- GLUE $4.93
- PSTL $15.55
- Average True Range (ATR)
- GLUE 0.21
- PSTL 0.24
- MACD
- GLUE 0.06
- PSTL 0.11
- Stochastic Oscillator
- GLUE 81.43
- PSTL 100.00
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
About PSTL Postal Realty Trust Inc.
Postal Realty Trust Inc is an internally managed real estate corporation that owns and manages properties leased to the United States Postal Service, or the USPS. Its objective is to create stockholder value by generating risk-adjusted returns through expanding its portfolio of owned and managed postal properties leased to the USPS. The majority of the revenue is generated from the rental income received.